EODData

MEMBERSHIP REGISTER LOG IN

LSE, 0QLR: Novartis AG

22 Sep 2025
LAST:

97.50

CHANGE:
 0.28		OPEN:
97.60		HIGH:
98.52		ASK:
101.58		VOLUME:
1.06M
CHG(%):
0.28		PREV:
97.77		LOW:
97.44		BID:
96.63		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
22 Sep 2597.6098.5297.4497.501.06M
19 Sep 2596.7298.1896.7297.771.35M
18 Sep 2597.0997.1596.2496.85627.7K
17 Sep 2596.3296.6896.0696.41309.3K
16 Sep 2597.6097.6796.7297.453.44M
15 Sep 2598.9499.1597.2397.37604.1K
12 Sep 2599.4099.9098.5898.931.08M
11 Sep 25101.36102.22101.24101.371.95M
10 Sep 25101.90102.28100.52100.542.38M
09 Sep 25102.23102.38101.58102.04528.8K

COMPANY PROFILE

Name:Novartis AG
About:Novartis AG engages in the research, development, manufacture, distribution, marketing, and sale of pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor for the treatment of symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Address:Lichtstrasse 35, Basel, Switzerland, 4056
Website:https://www.novartis.com
ISIN:CH0012005267
LEI:5493007HIVTX6SY6XD66

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

TECHNICAL INDICATORS

MA5:97.19
MA10:98.62
MA20:100.42
MA50:97.68
MA100:96.26
MA200:94.86
STO9:18.48
STO14:13.22
RSI14:37.36
WPR14:-86.64
MTM14:-4.33
ROC14:-0.04
ATR:1.63
Week High:99.15
Week Low:96.06
Month High:105.38
Month Low:96.06
Year High:105.38
Year Low:81.22

RECENT SPLITS

Date Ratio
04 Oct 20236-5

RECENT DIVIDENDS

Date Amount
11 Mar 2025$0.04
07 Mar 2024$0.03
09 Mar 2023$0.03
08 Mar 2022$0.03
04 Mar 2021$0.03
03 Mar 2020$0.03
04 Mar 2019$0.02
06 Mar 2018$0.02
02 Mar 2017$0.02
25 Feb 2016$0.02